SKIBSTED RUSSELL 4

What Happened
Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals (PCSA), reported an open-market purchase of 2,292 shares on May 29, 2026. The shares were acquired at $2.57 each for a total reported cost of $5,890. As a purchase (Form 4 code P), this represents an insider buy rather than a sale.

Key Details

• Transaction date: 2026-05-29; Filing date (Form 4): 2026-06-01 (timely filed).
• Price per share: $2.57; Shares purchased: 2,292; Total value: $5,890.
• Transaction type: Reported as an open-market purchase (code P).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes/plan: No 10b5-1 plan, tax-withholding, or other special footnotes were reported in the supplied details.

Context
Insider purchases can be interpreted by investors as a positive signal, but this is a relatively small-dollar buy. As CFO, Skibsted is a company insider, not a 10% owner; the filing is straightforward (no option exercise or gift). This report is factual disclosure of the transaction and does not explain the insider’s motivation.